Navigation Links
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
Date:12/10/2007

New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic

TSX Exchange Symbol: RVX

CALGARY, Dec. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

The Phase I clinical trial is taking place at a leading US contract research organization. The trial consist of three arms, an ascending single dose, a fed and fasted dose effect study, and a 7-day ascending multiple dose that will enroll a total of 70-80 healthy volunteers. The primary objective of the trial is to evaluate oral RVX-208 in healthy adult subjects for safety, tolerability, and pharmacokinetics. Results from this Phase 1a trial will be used for optimizing dosing for future trials including our Phase 1b trial.

Gregory S. Wagner, PhD, Senior Vice President, Preclinical Development of Resverlogix, stated that, "RVX-208 possesses a very favorable pharmacological and pharmaceutical profile. This compound is an excellent choice to be the first drug candidate from our preclinical pipeline, our research and development team has worked aggressively to rapidly advance it into clinical development."

"This field has been developing for 50 years. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in both animals and humans," stated Dr. Jan Johansson, MD, PhD. Senior Vice President of Clinical Affairs of Resverlogix. "We have identified a way to increase the endogenous production of ApoA-I via a small molecule drug. The initiation of this clinical trial is a milestone for the fi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Resverlogix is Presenting at IAS HDL Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Albany, New York (PRWEB) August 29, 2014 ... be valued at $5.6 billion in 2019. It ... 18.1% from 2013 to 2019, and was valued ... research report published by Transparency Market Research. , ... please visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
(Date:8/29/2014)... 29, 2014 Due to a misstatement posted ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... cell therapy research that might benefit ALS patients. Because ... new stem cell technologies and therapeutic applications, FRC listed ASCTC ... Challenge donors who wish not to support research that ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... Pharma ... SOMERVILLE, Mass., May 20 Spotfire, a,division of TIBCO ... Senior Director Life Sciences Analytics, will present,Applying Next Generation Business ... Conference being held May 20 & 21 in Basel,Switzerland. Mr. ...
... a considerable impact on many aspects of modern ... the human frontier, robotics is also vigorously engaged ... Interacting, exploring, and working with humans, the new ... The prospect of practical robots among humans follows ...
... Forward-Looking IVUS technology platform expected to enable, Volcano to ... ... therapeutic devices, SAN DIEGO, May 19 Volcano Corporation,(Nasdaq: ... and Optical Coherence Tomography (OCT) products designed,to enhance the diagnosis and ...
Cached Biology Technology:TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech 2TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech 3Robots moving closer to humans 2Volcano Announces Acquisition of Novelis, Inc. 2Volcano Announces Acquisition of Novelis, Inc. 3Volcano Announces Acquisition of Novelis, Inc. 4Volcano Announces Acquisition of Novelis, Inc. 5Volcano Announces Acquisition of Novelis, Inc. 6Volcano Announces Acquisition of Novelis, Inc. 7
(Date:8/29/2014)... release is available in German . ... players in the natural nitrogen cycle on Earth and ... bacteria were thought to depend on nitrite as their ... by Holger Daims, a microbiologist at the University of ... hydrogen as an alternative source of energy. The oxidation ...
(Date:8/29/2014)... MO. - In a cell,s nucleus, chromosomal DNA ... histones, an amalgam biologists call chromatin. Until about ... nuclear "sidekick," the mere packing material around which ... biologists have developed a greater appreciation for how ... investigators from multiple research institutions studying the sequence ...
(Date:8/28/2014)... TX Invasives is now available from the Lady Bird ... Austin for identifying harmful non-native plant, insect and other ... United States cause about $137 billion in economic and ... waterways, kill native plants and more. , "By having ... where invasive species occur, we,re more likely to catch ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... The National Institutes of Health has awarded Dr. Daniel Geschwind, ... a five-year, $10 million grant to continue his research on ... his investigations to include the genetics of autism in African ... fund collaborative work by Geschwind and experts at other autism ...
... A University of Alberta researcher has identified some of ... long distances. , Working together with an international ... examined unusual claw marks left on a river bottom ... major travel-way for dinosaurs., Alongside easily identified fossilized footprints ...
... N.Y. As the body ages, the physical effects ... becomes harder. But there are also less visible processes ... at work, which may contribute to age-related brain defects. ... the journal Nature Neuroscience CSHL Associate Professor ...
Cached Biology News:Autism in black and white: NIH grant helps scientist study disorder in African Americans 2CSHL neuroscientists show 'jumping genes' may contribute to aging-related brain defects 2CSHL neuroscientists show 'jumping genes' may contribute to aging-related brain defects 3
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Rabbit polyclonal to Orexin Prepro ( Abpromise for all tested applications). entrezGeneID: 3060 SwissProtID: O43612...
Adenylate kinase isoenzyme 6...
AK6 Antibody...
Biology Products: